

HUMAN ANTIBODIES AND HYBRIDOMAS-IV

26 – 28 April 1995

CONFERENCE PROGRAM

Wednesday 26 April 1995

- 07.45–08.45 Registration
- 08.45–09.00 Welcoming Remarks and Conference Overview
M.C. Glassy (Conference Chairman)
Hygeia Pharmaceuticals, San Diego, USA
- OVERVIEW LECTURE**
- 09.00–09.45 Phage display and its applications to in vitro immunization of human cells
C. Borraabaek
University of Lund, Sweden
- SESSION 1 CANCER**
- Moderators: **M.C. Glassy**
J. Jensenius
- 09.45–10.15 Human anti-colon adenocarcinoma antibody (cou1) reactive with modified cytokeratin: 18. Clinical and immunochemical investigations
J. Jensenius
University of Aarhus, Denmark
- 10.15–10.55 Cancer therapy with antibody-cytotoxic agent conjugates
A. Mountain
Celltech Research, UK
- 10.55–11.15 COFFEE
- 11.15–11.40 The human monoclonal antibody SC-1 induces apoptosis of stomach cancer cells
H.P. Vollmers, J. Dammrich, H. Ribbert, E. Wozniak, H.K. Muller-Hermelink
University of Wurzburg, Germany
- 11.40–12.05 Clinical evidence that the human monoclonal anti-idiotypic antibody 105AD7, delays tumour growth by stimulating anti-tumour T cell responses
L.C. Durrant, T.J.D. Buckley, R.A. Robins
University of Nottingham, UK
- 12.05–12.30 Generation and characterization of a human monoclonal antibody against lung carcinoma
S. Mukerjee, R.D. Medenica
Cancer Immuno-Biology Laboratory Inc, USA
- 12.00–12.15 Initial characterization of a human monoclonal antibody, derived from unimmunised normal peripheral blood lymphocytes, reactive against adenocarcinoma cells
D. Banerjee, R. Karim
Ontario Cancer Institute, Canada
- 12.15–12.45 Comparison of two radiolabelled human monoclonal antibodies in cancer detection and dosimetry
R.L. De Jager, J. Klein, J. H. Murray, M. Subramanian, B. Kobrin, M.V. Haspel, M.G. Hanna, Jr.
Perimmune, Inc., USA
- 12.45–14.00 LUNCH
- OVERVIEW LECTURE**

- 14.00–14.30 The potential of synthetic and hybridoma derived human antibodies to confer protection after passive immunisation
A.B. Lang, J.F. Viret, M. Vogel, B.M. Stadler
Swiss Serum and Vaccine Institute, Switzerland
- SESSION 2 INFECTIOUS DISEASES**
- Moderators: **A.B. Lang**
D. Burton
- 14.30–14.55 Neutralizing antibodies against HIV-1 from combinatorial phage display libraries
P.W.H.I. Parren, P.L. Earl, B. Moss, C.F. Barbas III, D.R. Burton
The Scripps Research Institute, USA
- 14.55–15.20 Cloning and biological characterization of human single chain Fv fragments that mediate neutralization of HIV-1 in vitro
V. Srikantan, B. Wang, K.E. Ugen, M. Satre, K. Dang, F. Scales, W.V. Williams, D.B. Weiner
University of Pennsylvania, USA
- 15.20–15.50 TEA
- 15.50–16.15 Potency of various human monoclonal antibodies in neutralization of HIV-1 primary isolates and lab strains
M.K. Gorny, C. Williams, S. Burda, S. Zolla-Pazner
New York University Medical Center, USA
- 16.15–16.30 Human monoclonal antibodies against a conformational domain of cytomegalovirus glycoprotein B
T. Boldicke, B. Haase, M. Bocher, W. Lindenmaier
Gesellschaft für Biotechnologische Forschung, Braunschweig, Germany
- 16.30–16.45 Neutralizing human monoclonal antibodies to RSV fusion protein isolated from Hu-SCID mice
P. Brams, S. Chamar, J.W. Ochi, D. Anderson
IDEC Pharmaceuticals, USA
- 16.45–17.00 **DISCUSSION**

Thursday 27 April 1995

- PLENARY LECTURE**
- 08.30–09.30 Unconjugated human or rodent MAbs for therapy? – A comparative appraisal of a complex molecule of action and requirements for optimal clinical effects.
H. Mellstedt
Karolinska Hospital, Stockholm, Sweden
- OVERVIEW LECTURE**
- 09.30–09.55 The pathogenic human monoclonal anti-DNA 1/16 that induce experimental systemic lupus erythematosus in mice is encoded by the VH4.21 gene segment.
Y. Shoenfeld, A. Waisman, M. Blank, P.H. Ruiz, E. Mozes
The Weizman Institute for Sciences, Israel

CONFERENCE PROGRAM

SESSION 3	AUTOIMMUNITY	14.30-14.55	Phage antibodies as useful immunochemical reagents A. Nissim, A.D. Griffiths, O. Hartley, S.C. Williams, I.M. Tomlinson, H.R. Hoogenboom, G. Flynn, C. Midgley, D. Lane, G. Winter <i>MRC Centre for Protein Engineering, UK</i>
Moderators:	Y. Shoenfeld F.K. Stevenson		
09.55-10.10	Mapping of therapy-induced antibodies to interferon-alpha 2 P. Kontsek, N.Fuschberger, D. Stancek <i>Slovak Academy of Sciences, Slovak Republic</i>	14.55-15.10	A new phage-display system to construct multicombinatorial libraries of very large antibody repertoires R. Sodoyer, F. Geoffroy, L. Aujaime <i>Pasteur Merieux S.V., France</i>
10.10-10.35	Dual recognition of lipid A and DNA by human antibodies encoded by the VH4-21 gene: a possible link between infection and lupus F.K. Stevenson, M.B. Spellerberg, C.J. Chapman, T.J. Hamblin <i>Southampton University Hospitals, UK</i>	15.10-15.35	Chain shuffling: a powerful tool for the manipulation of human antibodies H.R. Hoogenboom <i>Cambridge Antibody Technology, UK</i>
10.35-10.50	Human monoclonal anti-Rh antibodies produced by human-mouse heterohybridomas express the Gal a 1-3 Gal epitope E.L. Romano, R.F. Montano <i>IVIC - Venezuelan Institute for Scientific Research, Venezuela</i>	15.35-15.50	Phage-displayed antibodies specific for a cytoskeletal antigen: selection by competitive elution with a monoclonal antibody E.V. Meulemans, L. Nieland, W. Debie, F.C.S. Ramaekers, G.J.J.M. van Eys <i>University of Limburg, The Netherlands</i>
10.50-11.20	COFFEE	15.50-16.20	TEA
11.20-11.45	The Fc receptor III-mediated functional activity of human red cell antibodies is affected by the extent of galactosylation and by sequence changes in the CH2 domain B.M. Kumpel, Y. Wang, A.G. Hadley, C. Pilkinton, J.E.M. Gilmour <i>International Blood Reference Laboratory, UK</i>	16.20-16.45	A novel positional humanization method generates human consensus frameworks: humanized BrE-3 and Mc3 for breast cancer therapy J.R. Couto, R.L. Ceriani, J.A. Peterson <i>Cancer Research Fund of Contra Costa, USA</i>
11.45-12.00	Characterization of human antibody variable fragments against U1RNA-associated autoantigens, isolated from a synthetic- and patient-derived combinatorial library R.M.T. de Wildt, R. Finnern, W.H. Ouweland, A.D. Griffiths, W.J. van Venrooij, R.M.A. Hoet <i>University of Nijmegen, The Netherlands</i>	16.45-17.00	Chain shuffling of a high affinity scFv affects the fine specificity M. Ohlin <i>University of Lund, Sweden</i>
12.00- 12.15	Isolation of human recombinant anti-Rhesus D antibodies from a hyperimmunized donor S.M. Miescher, M. Vogel, P. Aeby, B. Brick, C. Biaggi, M. Rudolf, B.M. Stadler <i>University of Bern, Switzerland</i>	17.00-18.00	POSTER SESSION
12.15-12.30	Human monoclonal antibodies reactive with public determinants on HLA class I antigens A. Mulder, M.J. Kardol, J. Blom, M. Marrari, J.W. Bruning, R.J. Duquesnoy, F.J.H. Class <i>University Hospital Leiden, The Netherlands</i>		
12.30-12.45	Isolation and characterisation of autoantibodies from patients with autoimmune thyroid disease A. Bailey, J.M. Hexham, J. Furmaniak, B. Rees Smith, L.J. Partridge <i>University of Sheffield, UK</i>		
12.45-14.00	LUNCH		
14.00-14.30	OVERVIEW LECTURE Engineering Human antibodies for tumor therapy using phage display J.D. Marks, R. Schier, C. Adams, G. Appell, L. Weiber <i>University of California, USA</i>		
Session 4	MOLECULAR BIOLOGY		
Moderators	J.D. Marks M. Glassy		
			Friday 28 April 1995
			OVERVIEW LECTURE
		09.00-09.30	The development and characteristics of an explant procedure for investigating immune responses <i>in vitro</i> K. James, G. Skibinski, P. Hoffmann <i>University of Edinburgh, UK</i>
			SESSION 5
			EMERGING TECHNOLOGIES
			Moderators: K. James C. Borrebaeck
		09.30-09.55	Production of human antibodies by mice engineered with human immunoglobulin YACs A. Jakobvits <i>Cell Genesys Inc., USA</i>
		09.55-10.10	Use of miniaturized hollow fibre bioreactor for the development of human monoclonal antibodies from a patient with B-chronic lymphatic leukaemia S.O. Hahn, J. Hampe, U. Marx <i>Humboldt University Medical School (Charite), Germany</i>
		10.10-10.35	New approaches to human monoclonal antibody production: use of transgenic mice D. Fishwild, C. Carmack, F. Harding, S. Bernhard, S.O. Donnell, D. Munoz-O'Regan, T. Benoechea,

CONFERENCE PROGRAM

- V. Rohas, R. Mashayekh,
M. Trounstein et al...**
GenPharm International, USA
- 10.35–10.50 Production of human monoclonal antibodies in high concentration in the modular minifermenter miniPERM
F.W. Falkenberg, M. Ernst, H.O. Nagels
Ruhr-Universität Bochum, Germany
- 10.50–11.20 COFFEE
- 11.20–11.45 Getting what you want from phage display
J. McCafferty
Cambridge Antibody Technology, UK
- 11.45–12.00 Production of specific human antibodies by human lymphocytes engrafted in normal strains of mice
S. Dagan, I. Lubin, R. Eren, H. Marcus, M. David, Y. Reisner
Xenograft Technologies Ltd., Israel
- 12.00–12.25 Single-gene-encoded novel single-chain antibodies with anti-tumor cytolytic activity
S.V.S. Kashmiri, L. Shu, R. Bei, C.-F. Qi, H.-S. Lee, P. Horan-hand, E. Padlan, J. Schlom
National Cancer Institute, USA
- 12.25–14.00 LUNCH
- OVERVIEW LECTURE**
- 14.00–14.30 Development and characterization of human T-T cell hybridomas
C.D. Platsoucas
Temple University School of Medicine, USA
- SESSION 5 EMERGING TECHNOLOGIES (continued)**
- 14.30–14.55 Hybridoma rescue technology: generation of human monoclonal antibodies against respiratory Syncytia virus
Z.L. Jonak, K. Deen, K.B. Tan, S. Trulli, E. Henri, S. Demuth, K. Hallowell, M. Whitacre, S. Dillon, R. Sweet
Smithkline Beecham Pharmaceuticals, USA
- 14.55–15.10 Antigen-specific primary immune response of human B lymphocytes after *in vitro* immunization with GM3 ganglioside
M. Alfonso, B. Lanne, P. Ifversen, J. Portoukalian, J. Zeuthen
Danish Cancer Society, Denmark
- 15.10–15.25 Kinetic SAP: selecting on and off rates from phage libraries
M. Duenas
University of Lund, Sweden
- 15.25–15.40 Development of pharmaceutical formulations for therapeutic antibodies: monitoring of protein structure and stability
N.A. Guzman, R. Jin, S. Park, S. Begum, T. Tomsho, K. Iqbal
The R.W. Johnson Pharmaceutical Research Institute, USA
- 15.40–16.00 **DISCUSSION AND CLOSING REMARKS**
M.C. Glassy (Conference Chairman)
- 15.00 TEA AND DEPARTURE

POSTER PAPERS

- Characterization of biologically active ANCA Induced in mice: Pathogenic role in experimental vasculitis
Y. Shoenfeld, Y. Tomer, B. Gilburd, M. Blank, O. Lider, P. Fishman, R. Zigelman, P.L. Meroni, A. Wiik
The Weizman Institute of Science, Israel
- Pathogenic and non-pathogenic mouse anticardiolipin antibodies: binding properties and V gene analysis
Y. Shoenfeld, M. Blank, A. Waisman, E. Mozes
The Weizman Institute of Sciences, Israel
- Contamination of antibody preparations by bacterial peptidoglycans
A.J. Kulberg, S.B. Cheknev, A.A. Rodnikova
N.F. Gamaleya Epidemiology and Microbiology Institute, Russia
- Characterisation and labelling of hybridoma produced monoclonal antibody
V. Mehrotra, V.L. Lahiri
S.N. India
- Identification and reactivity of anti-Kelly monoclonal antibody
V. Mehrotra, V.L. Lahiri
S.N. India
- Characterization of a human monoclonal antibody against oxidised low density lipoprotein (oxi-LDL) secreted by hybridoma derived from lymphocytes of a patient with CAD
S. Kyurkchiev, I. Kehayov, Ch. Nachev, A. Gudev
Bulgarian Academy of Sciences, Bulgaria
- Construction of a heterohybridoma secreting human monoclonal antibodies against antigens specific to *Tr. pallidum*
I. Kehayov, S. Kyurkchiev, V. Terieza-Lazarova
Bulgarian Academy of Sciences, Bulgaria
- Macrophage subpopulations in the thymic hyperplasia of patients with myasthenia gravis
Jian Zhang, S. Cohen-Kaminsky, S. Berrih-Aknin
The John P. Research Institute, Canada
- Anti-tyrosinase antibodies in vitiligo, melanoma, and melanoma-associated hypopigmentation (MAH)
O. Merimsky, Y. Shoenfeld, E. Bahjarav, P. Fishman
Ichilov Hospital, Israel
- Human monoclonal antibodies to i blood group. Epstein-Barr virus (EBV) alters B cell glycolipid which is recognized by crossreactivity of these mAbs
Y. Nagatsuka, Y. Ono
Nihon University School of Medicine, Japan
- Antibodies specific for human thyrotropin receptor induce MHC antigen expression in thyroid cells
J. Charreire, S. Marion, L. Takorabet, J. Braun, A. Ropars
Inserm U. 283, Lille, France
- Human recombinant anti-Rhesus D antibodies: characterization and effector functions analysis
P. Klein, T. Ducrot, R. Beliard, A. Glacet, S. Moitel, J.-J. Huart, D. Bourel
Blood Transfusion Centre, Lille, France
- Immortalization of plasma cells by plasmid DNA
T. Kanki
Saitama Medical School, Japan
- Selection of non-competing monoclonal antibodies for a sandwich EIA
E. Pietrzykowski, R. Macfarlan, J. Cox
CSL Limited, Australia
- cDNA cloning and sequencing of variable region gene of monoclonal antibody SZ-39 specific for human brain glioma
S. Shen, Q. Huang, Z. Du
Suzhou Medical College P.R., China
- Characterization of the epitopes recognized by human antibodies against the tumor-associated polymorphic epithelial mucin
A. Rughetti, C. Petrarca, V. Turchi, C. Apollonj Ghetti, H. Rahimi, F. D'Agostini, L. Frati, M. Nuti
University of Rome, Italy
- Natural anti-idiotypic antibodies against a tumor immunoglobulin of a mucosa-associated lymphoid tissue lymphoma (MALT-type) occur in normal and gastritis patients
A. Greiner, H.K. Müller-Hermelink
University of Würzburg, Germany
- Production of anti-thyreoglobulin antibodies from a patient with MALT-type lymphoma associated with Hashimoto's thyroiditis
K. Markert, A. Greiner and H.K. Müller-Hermelink
University of Würzburg, Germany
- Mouse/human chimeric IgE antibodies directed to the house dust mite allergen Der p 2
J. Schuurman, T.E. Lourens, G.J. Perdok, P.W.H.I. Parren, R.C. Aalberse
Netherlands Red Cross, The Netherlands

*This program is correct at the time of printing, however the organisers reserve the right to make any changes that may be necessary.